IN2014DN03169A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN03169A IN2014DN03169A IN3169DEN2014A IN2014DN03169A IN 2014DN03169 A IN2014DN03169 A IN 2014DN03169A IN 3169DEN2014 A IN3169DEN2014 A IN 3169DEN2014A IN 2014DN03169 A IN2014DN03169 A IN 2014DN03169A
- Authority
- IN
- India
- Prior art keywords
- pioglitazone
- salt
- average
- time point
- sustained release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided is a sustained release preparation containing pioglitazone or a salt thereof as an active ingredient and showing superior sustainability. A sustained release preparation containing pioglitazone or a salt thereof which shows a dissolution ratio of pioglitazone of average 25 58% at the 2 hour time point and average 60 100% at the 4 hour time point in a dissolution test according to the 50 rpm USP Paddle Method and using pH 2.0 KC1/HC1 buffer at 37°C as a test solution.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011232302 | 2011-10-21 | ||
PCT/JP2012/077662 WO2013058409A1 (en) | 2011-10-21 | 2012-10-19 | Sustained-release preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN03169A true IN2014DN03169A (en) | 2015-05-22 |
Family
ID=47178262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3169DEN2014 IN2014DN03169A (en) | 2011-10-21 | 2012-10-19 |
Country Status (29)
Country | Link |
---|---|
US (1) | US9907789B2 (en) |
EP (1) | EP2768487B1 (en) |
JP (1) | JP6093762B2 (en) |
KR (1) | KR20140081826A (en) |
CN (1) | CN104039313A (en) |
AP (1) | AP2014007645A0 (en) |
AR (1) | AR088398A1 (en) |
AU (1) | AU2012326976B2 (en) |
BR (1) | BR112014008744A2 (en) |
CA (1) | CA2852417A1 (en) |
CL (1) | CL2014000992A1 (en) |
CO (1) | CO6960544A2 (en) |
CR (1) | CR20140213A (en) |
DO (1) | DOP2014000077A (en) |
EA (1) | EA201490840A1 (en) |
EC (1) | ECSP14013328A (en) |
IL (1) | IL232114A0 (en) |
IN (1) | IN2014DN03169A (en) |
MA (1) | MA35717B1 (en) |
MX (1) | MX2014004679A (en) |
NZ (1) | NZ624275A (en) |
PE (1) | PE20141189A1 (en) |
SG (2) | SG10201700121YA (en) |
TN (1) | TN2014000152A1 (en) |
TW (1) | TW201323018A (en) |
UA (1) | UA113858C2 (en) |
UY (1) | UY34403A (en) |
WO (1) | WO2013058409A1 (en) |
ZA (1) | ZA201403103B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2852417A1 (en) | 2011-10-21 | 2013-04-25 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
PE20141558A1 (en) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | DERIVATIVES OF BENZOTHIAZOLE-6-IL ACETIC ACID AND THEIR USE TO TREAT HIV INFECTION |
US20150141517A1 (en) * | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
KR102485766B1 (en) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | Pharmaceutical Composition Comprising Pioglitazone with Enhanced Bioavailability |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
JPH0624991A (en) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | Long acting preparation of ursodeoxycholic acid |
JPH0624959A (en) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | Medice release solid pharmaceutical preparation of gastric suspending type sustained |
DK0661045T3 (en) | 1992-09-18 | 2002-10-28 | Yamanouchi Pharma Co Ltd | Delayed release hydrogel preparation |
JPH06316517A (en) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | Sustained-release preparation |
AU8532798A (en) | 1997-06-13 | 1998-12-30 | Roland Bodmeier | Compounds which delay the release of active substances |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
EP1413315A4 (en) | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | Sustained-release medicines |
KR101363679B1 (en) | 2002-09-20 | 2014-02-14 | 안드렉스 랩스 엘엘씨 | Pharmaceutical tablet |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
JP4493970B2 (en) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | Sustained formulation |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
IN192749B (en) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
EP1607088B1 (en) | 2003-03-17 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Controlled release composition |
JP4933033B2 (en) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | Controlled release composition |
CN1802178A (en) | 2003-06-06 | 2006-07-12 | 武田药品工业株式会社 | Solid formulation |
JP2005015477A (en) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | Solid formulation |
US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
US8263121B2 (en) | 2004-04-14 | 2012-09-11 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
MX2007002375A (en) | 2004-08-31 | 2007-04-23 | Pfizer Prod Inc | Controlled release dosage forms combining immediate release and sustained release of low-solubility drug. |
US20080262047A1 (en) | 2005-09-22 | 2008-10-23 | Allen D Roses | Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients |
WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
UA91729C2 (en) | 2005-12-22 | 2010-08-25 | Такеда Фармасьютикал Компани Лимитед | Solid preparation |
TWI449542B (en) | 2006-03-30 | 2014-08-21 | Nippon Zoki Pharmaceutical Co | Solid pharmaceutical preparation |
TW200800299A (en) | 2006-04-27 | 2008-01-01 | Takeda Pharmaceutical | Pharmaceutical composition |
CN101674811B (en) | 2007-02-09 | 2015-08-19 | 阿尔法制药有限公司 | The dosage form of the active pharmaceutical ingredient containing two or more different physical aspects |
TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
CN101269040A (en) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | Pioglitazone hydrochloride sustained-release dropping pill and preparation method thereof |
WO2010039690A1 (en) | 2008-09-30 | 2010-04-08 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
TWI478712B (en) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | Pharmaceutical composition for modified release |
JP5827952B2 (en) | 2009-10-09 | 2015-12-02 | ユンジン・ファーム・カンパニー・リミテッドYungjin Pharm. Co. Ltd. | Pharmaceutical composition having both rapid action and durability |
JP2011232302A (en) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | Image inspection method and image inspection device |
CN101884627B (en) * | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | Pioglitazone hydrochloride gastric retentive sustained release tablet and preparation method thereof |
EP2665479B1 (en) * | 2011-01-10 | 2019-06-26 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
CA2852417A1 (en) | 2011-10-21 | 2013-04-25 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
KR20160056691A (en) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | Rechargeable battery |
-
2012
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 UA UAA201405332A patent/UA113858C2/en unknown
- 2012-10-19 TW TW101138592A patent/TW201323018A/en unknown
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en active Application Filing
- 2012-10-19 UY UY0001034403A patent/UY34403A/en not_active Application Discontinuation
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/en unknown
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/en unknown
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 EA EA201490840A patent/EA201490840A1/en unknown
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/en not_active IP Right Cessation
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 AR ARP120103908A patent/AR088398A1/en unknown
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/en not_active Expired - Fee Related
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/en active Pending
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/en not_active Application Discontinuation
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/en not_active Application Discontinuation
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/en unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/en unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/en unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/en unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/en unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009100264A3 (en) | Oral care product and methods of use thereof | |
MX369121B (en) | Aqueous pharmaceutical formulation of tapentadol for oral administration. | |
EP2883932A3 (en) | Aqueous solution and method for use thereof | |
MX358716B (en) | Oral care product and methods of use and manufacture thereof. | |
MX2012003296A (en) | Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin. | |
EA201270741A1 (en) | ORAL COMPOSITIONS AND LIPOPHYL SALTS OF METHylNALTREX | |
IN2014DN03169A (en) | ||
MY159492A (en) | Solid pharmaceutical formulation with delayed release | |
NZ600891A (en) | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs | |
AR083150A1 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE | |
EA201171399A1 (en) | METHOD AND COMPOSITION FOR IMPROVING SUCTION OF MEDICINES | |
EA201490175A1 (en) | COMPOSITIONS OF DEOXIC ACID AND ITS SALTS | |
ZA200904543B (en) | Salts, aqueous liquid compositions containing salts of S-(+)-abscisic acid and methods of their preparation | |
ZA201100535B (en) | Salts,aqueous liquid compositions containing salts of s-(+)-abscisic acid and methods of their preparation | |
EP2865664A4 (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
TR201001417A1 (en) | Cefdinir formulation with improved dissolution rate | |
PH12014502407B1 (en) | New alfentanil composition for the treatment of acute pain | |
MY163015A (en) | Dentifrice composition | |
IT1399923B1 (en) | PROCEDURE FOR THE PREPARATION OF SALTS OF THE ACID (R) ALPHA-LIPOIC THEIR FORMULATION AND USE IN PHARMACEUTICAL COMPOSITIONS IN THE FORM OF TABLETS THAT CONTAIN THEM | |
UA110933C2 (en) | Pharmaceutical composition for treatment of essential thrombocythemia | |
WO2013105924A3 (en) | Oral care compositions | |
WO2012064306A3 (en) | Effervescent formulations of rosuvastatin | |
TR201005241A1 (en) | Pregabalin solution formulation for controlled release. | |
WO2011121475A3 (en) | Modified release dosage form comprising desvenlafaxine or salts thereof | |
TH156810A (en) | Gradual release preparations |